Agents for use in the therapeutic or prophylactic treatment of retinal pigment epithelium associated diseases
OwnerSonghomitra PANDA-JONAS, Jost JONASinventors
Life of this patent
Estimating the term…
Abstract
The present invention relates to a pharmaceutical composition comprising an epidermal growth factor receptor (EGFR) agonist for use in the treatment of a retinal pigment epithelium (RPE) damage associated disease in a patient, wherein the EGFR agonist comprises the EGF family consensus amino acid sequence CX7CX4-5CX10-13CXCX5GXRC (SEQ ID NO: 1), wherein X is any proteogenic amino acid, wherein the RPE damage associated disease is selected from age-related macular degeneration (AMD), retinitis pigmentosa, cone-rod dystrophies or cone dystrophies, polypoidal choroidal vasculopathy, and Stargardt's disease.
Claims16
A method for treating a retinal pigment epithelium (RPE) damage associated disease in a patient, wherein the method comprises administering to the patient a pharmaceutical composition comprising an epidermal growth factor receptor (EGFR) agonist, wherein the EGFR agonist comprises the EGF family consensus amino acid sequence CX7CX4-5CX10-13CXCX5GXRC (SEQ ID NO:
- 1), wherein X is any proteogenic amino acid, wherein the RPE damage associated disease is selected from age-related macular degeneration (AMD), retinitis pigmentosa, cone-rod dystrophies or cone dystrophies, polypoidal choroidal vasculopathy, and Stargardt's disease.
Dependencies are inferred from the claim text.